Cancer
|

Preemptive immunotherapy with IL-15 activated cytokine-induced killer cells (CIK cells) for prevention of relapse in high-risk patients with acute leukemia and myelodysplastic syndromes after allogeneic stem cell transplantation

Institution: University Hospital Frankfurt, Department for Children and Adolescents, Division for Stem Cell Transplantation and Immunology
Applicants: Prof. Dr. med. Peter Bader, PD Dr. Eva Rettinger (Co-Applicant)
Funding line:
First and Second Applications
CIK-Tumor-Interaction
CIK-Tumor-Interaction
(© Eva Rettinger, Universtity Hospital Frankfurt)

Cytokine-induced killer (CIK) cells are a diverse group of immune cells consisting of T-lymphocytes and natural killer cells, which can be produced from mononuclear cells of a stem cell donor in 10-12 days. Administration of CIK-Cells may help to prevent the recurrence of malignant blood system disorders in patients who already underwent stem cell transplantation. This research study on the efficacy of CIK cells is carried out in close cooperation with the pediatric hospitals of Dusseldorf and Heidelberg as well as the medical centers in Frankfurt and Mainz.

Here you can get further information.